Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.
Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.
Patients can develop AEs with immunotherapies such as ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda), and there is a set of AEs they can get with the BRAF inhibitors. The most common AE with checkpoint inhibitors, for all organs, is rash. It is often fairly mild, and it can usually be treated with topical steroids or oral antihistamines, Stein explains. More severe but rare AEs include bullous pemphigoid, Stevens-Johnson syndrome, or toxic epidermal necrolysis.
There are severe allergic reactions in which the skin starts to blister and actually peel off, Stein adds. While they can be life-threatening, they are pretty rare.
MK-1084 Alone and Plus Pembrolizumab Shows Early Safety, Activity in KRAS G12C+ Solid Tumors
First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC
Concurrent Durvalumab/CRT Does Not Confer Significant Survival Advantage in Unresectable Stage III NSCLC
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
2 Commerce Drive
Cranbury, NJ 08512